Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies-Reference-Cited by-同舟云学术

Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies

Published:2019-05 Issue:3 Volume:25 Page:398-407
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Volkers Peter¹,Hanschmann Kay‐Martin¹,Calvez Thierry²,Chambost Hervé³,Collins Peter W.⁴,Demiguel Virginie⁵,Hart Daniel P.⁶,Hay Charles R.M.⁷^ORCID,Goudemand Jenny⁸,Ljung Rolf⁹,Palmer Ben P.¹⁰,Santagostino Elena¹¹,van Hardeveld Ella M.¹²,van den Berg Marijke¹²,Keller‐Stanislawski Brigitte¹^ORCID

Affiliation:

1. Paul‐Ehrlich‐Institut Langen Germany

2. INSERM, Institut Pierre Louis d'Épidémiologie et de Santé publique Sorbonne Universités Paris France

3. Service d'Hématologie Oncologie Pédiatrique, La Timone APHM and Aix Marseille Université Marseille France

4. The University Department of Haematology University Hospital of Wales Hospital Cardiff UK

5. Santé publique France French National Public Health Agency Saint‐Maurice France

6. Barts and The London School of Medicine & Dentistry, The Royal London Hospital Haemophilia Centre QMUL London UK

7. Department of Haematology, Manchester Royal Infirmary Manchester University Manchester UK

8. Service d'Hématologie et de Transfusion, Faculté de Médecine, Centre Hospitalier Universitaire de Lille Université Lille 2 Lille France

9. Department of Clinical Sciences–Paediatrics Lund University Lund Sweden

10. The United Kingdom National Haemophilia Database Manchester UK

11. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy

12. PedNet Haemophilia Research Foundation Baarn The Netherlands

Funder

Paul-Ehrlich-Institut

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13747

Reference28 articles.

1. Inhibitors in haemophilia: what have we learned from registries? A systematic review

2. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

3. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort

4. Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients

5. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of emicizumab prophylaxis for haemophilia A with inhibitors: an adaptive health technology assessment for the Indian setting;BMJ Evidence-Based Medicine;2024-05-06

2. The use of Bacillus subtilis as a cost-effective expression system for production of Cholera Toxin B fused factor VIII epitope regions applicable for inducing oral immune tolerance;Folia Microbiologica;2024-04-29

3. Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A;Blood Reviews;2023-12

4. In vivo genome editing using 244-cis LNPs and low-dose AAV achieves therapeutic threshold in hemophilia A mice;Molecular Therapy - Nucleic Acids;2023-12

5. Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada;Research and Practice in Thrombosis and Haemostasis;2023-11